BIOUNIVERSA s.r.l. nasce come Spin-Off dell’Università degli Studi di Salerno nel 2009 e opera nel settore delle biotecnologie applicate alla salute dell’uomo (red biotech).
I progetti di ricerca condotti dal Prof. Arturo Leone (†) e dalla Prof.ssa Maria Caterina Turco sullo stress e sull’apoptosi cellulare sono i pilastri scientifici su cui si basa BIOUNIVERSA. Il loro lavoro seminale ha reso possibile ottenere un primo Brevetto alla fine del 2009 (esteso successivamente in Europa e negli USA).
Da allora, un significativo numero di dati scientifici relativi alle proprietà biologiche della proteina BAG3 sulla regolazione della morte cellulare sono stati pubblicati dai componenti del Team su importanti riviste scientifiche.
Biouniversa ha scoperto che l’inibizione della proteina BAG3 stimola il sistema immune ad attaccare il tumore, in particolare l’adenocarcinoma pancreatico.
Da questo nasce la produzione di un anticorpo ad uso terapeutico per patologie oncologiche e non oncologiche.
In BIOUNIVERSA sono entrati due Fondi di Venture Capital nel 2010:
– INDACO Venture partners SGR (TT Ventures)
Board of Directors
Dr. Giovanni Rizzo received his Biology degree at the “La Sapienza” University of Rome, his PhD in Oncology and his specialization in microbiology at the University of Perugia, Italy, his post-graduate qualification in preclinical and clinical development of drugs from University “La Bicocca” Milano and his Master in Business Administration (MBA) at the HULT International Business School, London.
Dr. Rizzo has as extensive experience in drug discovery and development and in medical device development. He was head of biology of Intercept Pharmaceuticals Inc.; Consultant at Index Ventures (MediXci), a venture capital firm; CEO of iDNA Ltd, a drug discovery service company; Vice President of Yaqrit Ltd, a spin off company of the University College London, member of board of directors and Chief of Innovation Division of Zcube, Zambon group.
He also holds an honorary research position at the University College London (UCL) in the Institute of Liver and Digestive Health (ILDH) and invited professor to the Milano Biococca.
Dr. Rizzo is an entrepreneur and an investor himself with the London Business Angels (LBA); and he is board member of the Italian Angels for Biotech, Italy.
Membro del C.d.A
- PhD MB, esperienza pluriennale nelle aree accademiche ed industriali
- Membro del Consiglio Scientifico di Gerontopole (Toulose)
- Editore Associato del Journal of Nutrition, Health and Aging (JNHA) e di The Journal of Prevention of Alzheimer’s Disease (JPAD)
- Ex Direttore Associato (Cluster Leader) di Early to Candidate (E2C) DPU, Sanofi, Toulose (France)
- Ex Direttore del reparto scientifico di R&S , Sanofi-Aventis, Toulose, France
- Ex Capo del Dipartimento di Trombosi Cardiovascolare, Sanofi-Synthelabo, Montpellier, France.
Giovanni De Caro
Membro del C.d.A.
- Chief Investor Officer di Step Venture
- Partner di Zephiro Investments
- Responsabile dello sviluppo del portafoglio strategico di Healthware International
- Membro del CdA di Campania New Steel, l’incubatore di Città della Scienza e della Federico II
- Membro del CdA di Spinvector, Biouniversa e TXC
- Vent’anni in IntesaSanpaolo nel private equity e nel venture capital
Presidente del C.d.A.
Elizabeth Robinson is a co-founder and Vice Chairman of Indaco Venture Partners SGR.
Previously she served as Investment Director of the TTVenture fund from 2014 to mid 2018 and was a Venture Consultant for Sofinnova Partners in Paris from 2005-2008. She has been an active Angel investor for over 10 years.
Elizabeth has broad experience in life sciences and the development and licensing of innovative pharmaceutical products. She was a co-founder of NicOx S.A.(1997) and has been President of NicOx Research Institute Srl since January 2006. She serves on the Board of Directors of several lifescience companies including MolMed (listed on the Milan Stock Exchange MLMD.MI).
In her career, Elizabeth has served as Director, Product Development, at Recordati Italy (1990-1996); Consultant, Technology Development, at Techint Engineering Company (1988-1990); Vice President, New Technology Ventures Europe, at Genzyme (1985-1988); Visiting Scientist at MIT (1984-1987); and Post Doctorate Research Associate at MIT (1982-1984).
Elizabeth graduated Phi Beta Kappa from Wellesley College in 1977, received her M.S. in Chemical Engineering from Massachusetts Institute of Technology in 1979 and her Ph.D. in biotechnology from MIT in 1982.
She is a member of the Fulbright Commission in Italy .
Elizabeth is a contributing author on the chapter of patent due diligence for investors sponsored by the World Intellectual Property Organization.
Maria Caterina Turco
MD, PhD, Prof. of Biochemistry – University of Salerno (Italy)
100+ per-reviewed publications
Prof. of Entrepreneurship and Innovation – University of Salerno (Italy)
Vincenzo De Laurenzi
MD, PhD, Prof. of Clinical Biochemistry and Molecular Biology – University G. D’Annunzio, Chieti (Italy)
90+ peer-reviewed publications
PhD. Prof. of Biochemistry at Department of Medicine Surgery and Dentistry – University of Salerno
40+ peer-reviewed publications on BAG3
PhD, Prof. of Biochemistry – University of Salerno
20+ peer-reviewed publications on BAG3, stress- and metallo-proteins
International scientific committee
Prof. Michael Karin
Department of Pharmacology – University of California, San Diego-CA, USA
Prof. David Tuveson
Cold Spring Harbor Laboratory, NY, USA